TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: NUDGE-EHR Replication Trial at Mass General Brigham

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Primary care provider at Mass General Brigham~Providers will receive these EHR tools for their patients who meet the following criteria:~1. older adults (aged 65 years or more)~2. who have been prescribed at least 90 pills of benzodiazepine or sedative hypnotic in the last 180 days.~Outcomes will be measured on the patient level.~Exclusion Criteria:~* N/A

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- No Alert (Usual Care) (Type: NO_INTERVENTION): Providers randomized to usual care will receive no intervention.
- Open Encounter + Pre-commitment (Type: EXPERIMENTAL): There will be an enhanced EHR alert, known as a Best Practice Advisory \[BPA\], which will appear on each provider's EHR screen. We will also test a two-staged pre-commitment BPA in which the providers are prompted to discuss risks of the high-risk medications and share a handout about risks with their patients.
- Open Encounter + Follow-up booster (Type: EXPERIMENTAL): There will be an enhanced EHR alert, known as a Best Practice Advisory \[BPA\], which will appear on each provider's EHR screen. We will add a boostering option in the enhanced BPA, which is a provider-directed option for a follow-up in-basket message sent 4 weeks after the BPA is triggered.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria~* Subjects must be able to understand and communicate with the investigator and comply with the requirements of the study and must give a written, signed and dated informed consent before any study assessment is performed~* Subjects must have participated in core study CAIN457F2306, and must have completed the entire treatment period~* Subjects must be deemed by the investigator to benefit from continued secukinumab therapy~Exclusion criteria~* Any subject taking other concomitant biologic immunomodulating agent(s) except secukinumab~* Any subject who is deemed not to be benefiting from the study treatment based upon lack of improvement or worsening of their symptoms~* Pregnant or nursing (lactating) women~* Women of child-bearing potential, unless they are using effective methods of contraception during the entire study or longer if required by locally approved prescribing information (e.g., 20 weeks in EU)~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Secukinumab 75mg (Type: EXPERIMENTAL): Subjects continued to receive secukinumab 75mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator
- Secukinumab 150mg (Type: EXPERIMENTAL): Subjects continued to receive secukinumab 150mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 300 mg as judged appropriate by the investigator
- Placebo - AIN457A 75mg (Type: EXPERIMENTAL): Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 0.5 mL solution solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 75mg
- Placebo - AIN457 150mg (Type: EXPERIMENTAL): Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 1 mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 150 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Training Attention and Eye Movement in ASD

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant has a diagnosis of Autism Spectrum Disorder (on Diagnostic and Statistical Manual -IV, Autism Diagnostic Observation Schedule, Autism Diagnostic Interview-Revised)~* Participant has a nonverbal Intelligence Quotient (IQ) of 85 or greater and verbal IQ of 70 or greater~* Cooperative and able to follow instructions~* Normal hearing acuity~* Normal or corrected-to-normal vision~Exclusion Criteria:~* Major medical or neurological problems including seizures, diagnosed epileptiform EEG abnormalities, migraine, tuberous sclerosis, fragile X, static encephalopathies resulting from prior Central Nervous System insults, significant premature birth, and history of exposure to teratogens, metabolic abnormalities, and history of head trauma, cerebral palsy, stroke, meningitis, brain tumor or additional psychiatric diagnoses~* Participants currently participating in vision therapy will be excluded

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- Eye Movement Game Control (Type: EXPERIMENTAL): Cognitive Training Eye Motor Training
- Hand Movement Game Control (Type: ACTIVE_COMPARATOR): Cognitive Training Hand Motor Training

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Two-part Single and Multiple Dose Study to Assess the Safety , Pharmacokinetics and Effects of AZD3293 in Healthy Japanese Young and Elderly Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Japanese elderly and young males and females (of non-childbearing potential)~* Body mass index (BMI) between 17 and 27 kg/m2 and weigh at least 40 kg and no more than 100 kg~Exclusion Criteria:~* Psychiatric disease/condition, GI, renal, hepatic, cardiovascular, psychiatric, or retinal diseases or disorders~* Use of antipsychotic drugs , or chronic use of antidepressant or anxiolytic drugs.~* Frequent use (more than 2 days per week during the last 12 weeks) of tobacco or other nicotine products.~* Neurological disease, including seizures, recent memory impairment, or clinically significant head injury.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- AZD3293 (Type: EXPERIMENTAL): AZD3293 will be administered as single dose of an oral solution in Part 1 and single and multiple doses of an oral solution in Part 2. The ascending doses are planned to be 15, 50 and 150 mg for young subjects in Part 1 and 15 and 50 mg for elderly subjects in Part 2. Before proceeding to next dose level, safety, tolerability and pharmacokinetic data from the previous cohort(s) will be evaluated by a Safety Review Committee. Part 2 will start after confirming safety and tolerability in Part 1.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo given (2 subjects in each cohort)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* female participants, \>=18 years of age;~* stage III, or inflammatory breast cancer;~* estrogen receptor/progesterone receptor (ER/PgR) positive or negative and human epidermal growth factor receptor 2 (HER-2) negative;~* normal left ventricular ejection fraction (LVEF).~Exclusion Criteria:~* previous chemotherapy/endocrine therapy;~* evidence of distant metastatic disease;~* other primary tumors in last 5 years (except for adequately treated cancer in situ of the cervix, or basal cell skin cancer);~* chronic daily treatment with \>325 milligram per day (mg/day) aspirin, or \>75mg/day clopidogrel.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab (Type: EXPERIMENTAL): Participants will receive FEC, followed by paclitaxel, given concomitantly with bevacizumab for approximately 3-12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Non-infectious anterior uveitis~* Grade 1 - Grade 3 anterior chamber cell count~* Subjects must have Intraocular pressure \<25 mmHg at baseline and may only administer a maximum of 1 topical medication to control Intraocular pressure in the study eye.~* Visual acuity ≥ 20/200 in the study eye~Exclusion Criteria:~* Severe/serious ocular pathology~* Active intermediate or posterior uveitis.~* Previous anterior uveitis episode in the study eye within 4 weeks of Visit 1~* Oral corticosteroids within 14 days of Visit 1~* Intravitreal or sub-Tenon corticosteroid treatment in the study eye within the past 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- NS2 (Type: EXPERIMENTAL): NS2 ophthalmic drops (0.5%) in the affected eye
- NS2 and Pred Forte (Type: EXPERIMENTAL): NS2 ophthalmic drops (0.5%) and Prednisolone acetate ophthalmic suspension (1%) in the affected eye
- Pred Forte (Type: ACTIVE_COMPARATOR): Prednisolone acetate ophthalmic suspension (1%) in the affected eye

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Xyrem for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson's Disease (PD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female with a diagnosis of idiopathic PD.~* Age between 30 and 75, inclusive. -Hoehn \& Yahr Stage 1.5 - 4.0 in the practically defined medication OFF. -~* History \> 2 months of excessive daytime sleepiness confirmed at baseline/screening by an Epworth Sleepiness Scale score of \> 10.~* History \> 2 months of nocturnal sleep disturbances consisting of insomnia, fragmented sleep and/or non-restorative sleep.~* Folstein Mini-Mental State Exam score of \> 24.~* Birth control for sexually active women of childbearing potential (e.g. abstinence, hormonal contraception, barrier method, intrauterine device).~* Evidence of a personally signed and dated informed consent form document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the trial.~* Subjects who are willing and able to comply with scheduled visits, treatment plan, and other study procedures.~* Stable dose of medications, defined as no change in dose or regimen of medications for at least 3 months prior to Screen Visit.~Exclusion Criteria:~* Known idiopathic sleep pathology: sleep apnea and narcolepsy.~* Serious co-morbid disease --Atypical parkinsonism (e.g., Parkinson plus syndrome, secondary Parkinson's syndrome). --Significant neurological symptoms not accounted for by PD. --Significant psychiatric symptoms or dementia.~* Sexually active women of childbearing potential without adequate form of birth control.~* Pregnancy or lactation.~* Mini-mental status examination of \< 25.~* Participation in another clinical trial of another investigational agent or device within the previous 60 days.~* Current abuse of alcohol or drugs.~* Active or prior malignancy other than cutaneous basal cell carcinoma or in situ carcinoma of the uterine cervix.~* Known hypersensitivity to sodium oxybate or other constituents of the product.~* Any medical conditions that are contraindications to the use of sodium oxybate or significant hepatic impairment.~* Patients being treated with sedative hypnotic agents or other central nervous system (CNS) depressants.~* Subjects taking warfarin.~* Patients with succinic semialdehyde dehydrogenase deficiency.~* Subjects who, in the opinion of the investigator, are not able to comply with the requirements of the study.~* Any other condition that, in the investigator's opinion, would cause a significant hazard to the subject.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Xyrem in Parkinson disease (Type: EXPERIMENTAL): sodium oxybate 4.5 to 9.0 gms per night

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (at least 18 years old)~* Plasma HIV RNA \> 1000 copies/ml~* HIV-1-infection confirmed by ELISA and Western blot or Immunofluorescence~* ART naïve patients or~* ART for less than 3 months and more than 6 months ago ; an HIV resistance genotype at baseline showing no mutation to NNRTI and TDF or 3TC will be required~* For women of childbearing age, negative urinary test for pregnancy and to accept contraceptive methods: condom use and intra-uterine device when possible or declare no wish of pregnancy in the coming year.~* Confirmed or probable TB~* TB treatment including rifampin started since 2 to 8 weeks before randomisation~* Signed informed consent form~* For French patients, to be affiliated to the National Health Care System~Exclusion Criteria:~* HIV-2 infection (single or with HIV-1)~* Woman who is pregnant or likely to become so, is breastfeeding or refuses to use contraception~* ALT\>2.5N, Hb \<7g/dl, neutrophils \< 750/mm3, platelet\<50 000/mm3, bilirubin \>5N, lipase \>3N~* Creatinine clearance \<60ml/min as assessed by the Cockcroft method~* Ongoing psychiatric pathology or any condition (including, but not limited to, the consumption of alcohol or drugs) which might, in the investigator's opinion, compromise the safety of treatment and/or patient compliance with the protocol~* Concomitant treatments including phenytoin or phenobarbital (compounds interacting with UGT1A1)~* Prior TB with a Mycobacterium tuberculosis strain resistant to rifampin~* TB treatment started for more than 8 weeks before randomisation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): efavirenz
- 2 (Type: EXPERIMENTAL): raltegravir 400 mg
- 3 (Type: EXPERIMENTAL): raltegravir 800 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Women's Health Initiative (WHI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Postmenopausal women ages 50 to 79.

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Acute Hemodynamic Effects of Sildenafil in Patients With Severe Aortic Stenosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Severe aortic stenosis (AVA \< 1.0 cm2)~* Referred for a clinically ordered right and left heart catheterization~* 18 years of age and older~* Able and willing to comply with all requirements of the study~Exclusion Criteria:~* Nitrate use within 24 hours~* SBP \< 110 mmHg or MAP \< 75 mmHg~* Severe mitral regurgitation~* Severe aortic regurgitation~* Increased risk of priapism~* Retinal or optic nerve problems or unexplained visual disturbance~* Alpha antagonists or cytochrome P450 3A4 inhibitors use within 24 hours~* Current or recent (≤ 30 days) acute coronary syndrome~* O2 sat \< 90% on room air~* Females that are pregnant or believe they may be pregnant~* Any condition which the PI determines will place the subject at increased risk or is likely to yield unreliable hemodynamic data~* Unwilling to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sildenafil 40mg or 80mg (Type: EXPERIMENTAL): A single oral dose of Sildenafil (either 40mg or 80mg) will be administered to a participant after baseline hemodynamics are measured in the catheterization lab. Each dose will be equally distributed among those with preserved (≥50%) and reduced (\<50%) EF.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Symptoms of RA for no more than 12 months prior to enrollment~* Meet American College of Rheumatology/European League against Rheumatism (ACR/EULAR) 2010 criteria for classification of RA~* Treated with Methotrexate (MTX) for at least 12 weeks prior to randomization with a stable oral dose for at least 4 weeks, Subjects must randomize on the maximum tolerated dose of oral methotrexate (minimum of 15 mg and maximum of 25 mg per week), dose of MTX \< 15 mg/week but ≥ 7.5 mg/week is permitted if subjects are intolerant to higher doses~* At least 3 tender \& 3 swollen joints~* Anti-cyclic citrullinated peptide (CCP) \> 3X the upper limit of normal and positive rheumatoid factor~Exclusion Criteria:~* History of other autoimmune diseases (eg, psoriasis, systemic lupus, erythematosus, etc)~* Prior use of non-biologic therapy other than methotrexate~* Prior use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (DMARD) therapy~* Subjects with chronic or recent acute serious infection~Other protocol defined inclusion/exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment A (Type: EXPERIMENTAL): Abatacept Single Blind Treatment Period
- Treatment B (Type: ACTIVE_COMPARATOR): Adalimumab Single Blind Treatment Period
- Treatment C (Type: ACTIVE_COMPARATOR): Abatacept Cumulative Treatment Period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically or cytologically confirmed adenocarcinoma of the prostate;~2. Ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH) analogue or inhibitor, or orchiectomy (i.e., surgical or medical castration);~3. Progressive disease after medical or surgical castration,~Exclusion Criteria:~1. Metastases in the brain or active epidural disease. (Note: patients with treated epidural disease are allowed);

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): MDV3100

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete